Stockscreener 앱 받기
3.65
7.12%
-0.28
시간 외 거래:
3.84
0.19
+5.21%
전일 마감가:
$3.93
열려 있는:
$3.97
하루 거래량:
68,027
Relative Volume:
0.73
시가총액:
$126.25M
수익:
-
순이익/손실:
$-35.46M
주가수익비율:
-8.6534
EPS:
-0.4218
순현금흐름:
$-34.00M
1주 성능:
-20.13%
1개월 성능:
+3.99%
6개월 성능:
-73.45%
1년 성능:
-80.84%
1일 변동 폭
$3.57
$4.05
1주일 범위
$3.57
$4.8791
52주 변동 폭
$3.35
$22.00
Contineum Therapeutics Inc Stock (CTNM) Company Profile
명칭
Contineum Therapeutics Inc
전화
(858) 333-5280
주소
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
CTNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
3.65 | 126.25M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-22 | 개시 | Robert W. Baird | Outperform |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-30 | 개시 | Stifel | Buy |
Contineum Therapeutics Inc 주식(CTNM)의 최신 뉴스
Contineum initiated with an Outperform at William Blair - TipRanks
Bank of America Corp DE Increases Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Long Term Trading Analysis for (CTNM) - news.stocktradersdaily.com
13,307 Shares in Contineum Therapeutics, Inc. (NASDAQ:CTNM) Acquired by Nuveen Asset Management LLC - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Deutsche Bank AG Purchases New Shares in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Northern Trust Corp Increases Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics ATM - Leerink Partners
Contineum Therapeutics’ SWOT analysis: pipeline progress buoys stock outlook By Investing.com - Investing.com South Africa
Contineum Therapeutics’ SWOT analysis: pipeline progress buoys stock outlook - Investing.com
Contineum Therapeutics (NASDAQ:CTNM) Price Target Lowered to $20.00 at Morgan Stanley - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Earns Outperform Rating from Royal Bank of Canada - Defense World
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference - BioSpace
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - BioSpace
Contineum Therapeutics May 2025 slides: Multiple shots on goal with 2H25 catalysts ahead - Investing.com India
Barclays PLC Buys 7,978 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Wells Fargo & Company MN Raises Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics (CTNM) Expected to Announce Earnings on Thursday - Defense World
(CTNM) Investment Analysis - news.stocktradersdaily.com
Contineum Therapeutics (NASDAQ:CTNM) versus Longeveron (NASDAQ:LGVN) Financial Survey - Defense World
JPMorgan Chase & Co. Has $416,000 Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., As Chief Medical Officer - citybiz
Geode Capital Management LLC Purchases 59,732 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development - BioSpace
Contineum Therapeutics Appoints Timothy Watkins As Chief Medical Officer And Head Of Development - marketscreener.com
Form 8-KCurrent report - ADVFN
Critical Contrast: Contineum Therapeutics (CTNM) and Its Rivals - Defense World
We're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Rate - Yahoo Finance
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - ADVFN
(CTNM) On The My Stocks Page - news.stocktradersdaily.com
Contineum Therapeutics (CTNM) vs. Its Competitors Head-To-Head Survey - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $24.80 Consensus PT from Analysts - Defense World
Contineum Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Contineum Therapeutics Rings the Closing Bell - Nasdaq
How the (CTNM) price action is used to our Advantage - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Has $811,000 Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Charles Schwab Investment Management Inc. Buys 12,035 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - The AM Reporter
Bank of New York Mellon Corp Has $275,000 Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - BioSpace
Analysts Set Contineum Therapeutics, Inc. (NASDAQ:CTNM) Target Price at $24.80 - Defense World
(CTNM) Investment Report - news.stocktradersdaily.com
Jones Trading Begins Coverage on Contineum Therapeutics (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Inc (CTNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Contineum Therapeutics Inc 주식 (CTNM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lorrain Daniel S. | Chief Scientific Officer |
Nov 18 '24 |
Sale |
16.38 |
6,190 |
101,421 |
169,572 |
2.13%
1.01%
자본화:
|
볼륨(24시간):